PORTFOLIO COMPANIES

Psygen is a manufacturer of pharmaceutical-grade psychedelic API products for pre-clinical and clinical research and, eventually commercial therapeutic applications. The Company’s principal products are psilocybin and DMT. Psygen also intends to pursue a drug development program for the application of LSD in psychotherapy.

Wesana is on a mission to treat traumatic brain injury and other mental health ailments using psilocybin and other natural therapies. Through extensive clinical research and academic partnerships, Wesana is developing evidence- based formulations and protocols to help patients overcome neurological, psychological and mental health ailments caused by trauma.

Awakn Life Sciences is a biotechnology company with clinical operations researching, developing, and delivering psychedelic new chemical entity drugs and therapies to treat Addiction. Awakn is integrating psychedelic medicine into mainstream healthcare to enable better mental health for more people through Research, Digital, Clinics, and Ecosystems.

PsyTech is building a vibrant brand that lives at the intersection of clinical therapy, software solutions and community — all designed to explore psychedelic health and wellness, combat stigma, treat patients and accelerate innovation. Empowered by the advancement of groundbreaking clinical research, the team fosters and steers innovation in psychedelics to serve the greater good.

TRIPP Fitness For Your Inner Self, is an innovative research driven solution designed to help you manage your emotional well-being through the immersion of virtual reality. Based on evidence-based neuroscience research, TRIPP is a powerful digital toolkit that is designed to change the way you feel.

Psilera is reimagining psychoactive natural products as building blocks for the next generation of neurological therapeutics. Natural medicines have been around long before the current pharmaceutical industry and often serve as starting points for pharmaceutical innovation. Psilera knows psychedelics have the potential to change the way the world thinks, and they utilize centuries of knowledge and apply 21st century technology and innovation to make that happen.

Nucleus Holding is a holding company founded by Iter Investments to build a portfolio of data assets and media assets that will collectively represent the broad ecosystem of the psychedelic industry. The first subsidiaries of Nucleus Holding are (1) Psychedelic Invest, which has grown to become the leading psychedelic media platform for those looking to invest in the psychedelic industry and includes the first Psychedelic Index; and (2) Neuly, which is focused on building the largest database of psychedelic information to provide data and insights relating to the psychedelic ecosystem. Nucleus Holding will serve as the central resource for patients, customers, investors, businesses, therapists, clinicians, and other groups interested in learning more about the burgeoning psychedelic industry.

Founded in 2019, Beckley Psytech is a for-profit company dedicated to helping patients suffering from neurological and psychiatric disorders by developing a pipeline of psychedelic compounds into licensed pharmaceutical medicines. Our vision, supplemented by our partnership with the Beckley Foundation, is for clinically validated psychedelic medicines to be integrated into modern medical practice in order to help patients in need around the world suffering with these profoundly debilitating conditions.

APEX is drug development company and its lead clinical candidate is a synthetic psilocin for the treatment of PTSD, which would be one of the first Canadian phase 2 clinical trials for psilocin. APEX plans to develop drug products from both synthetic and botanically sourced compounds, differentiating APEX from the pack by diversifying APEX’s options for commercialization of drug products.

Clairvoyant Therapeutics is a Canadian biotech company focused on psychedelic therapy drug development for addiction. Clairvoyant is at the forefront of a growing psychedelic therapy industry and operates under the principles of open science. Our team has a successful track record of designing and operating clinical trials and bringing new drugs to market.

aNUma was founded to help individuals become their best selves by overcoming the problems of modernity including addiction, loneliness, depression and anxiety. We believe technology that revitalizes the bonds between self and other - strengthening capacities underlying the social fabric while building psychologically resilient individuals - is exactly what the world needs now.

Reset Pharma is a privately-held biotechnology company focused on the development and commercialization of novel psychedelic treatments for patients with life-threatening illnesses, including cancer. The company’s lead program focuses on psilocybin with psychotherapy for patients with cancer related demoralization, anxiety and depression. Reset Pharma has established a highly experienced biotech development team and has a Scientific Advisory Board of leading experts in psychiatry, oncology and psychedelics.

Quantified Citizen is a flexible platform for easily building and administering studies. Our platform is designed to accelerate the pace and quality of health research. Using a range of mobile- access tools, we empower researchers to decentrally build, distribute and administer studies. By automating and simplifying clinical research, we enable researchers to spend more time thinking, analyzing, and problem solving, and less time doing administrative work.

Freedom Bio is a clinical stage biotech platform with phase 2 programs and 4 pre-clinical programs addressing the biggest shortcoming of first generation psychedelics. The company’s programs are based on 30+ years of work at Dr. John Krystal’s lab at Yale University.

MAPS is formed as a non-profit and public benefits corporation and is in Phase 3 clinical trials for MDMA for PTSD. MAPS expects to have approval from the FDA by 2023. As a non-profit, MAPS cannot receive equity financing. Thus, this SPV was set up to provide investors with revenue share payments based on North America sales of MDMA for use in MDMA-assisted therapy.

Founded in 2019 by Dr. Ingmar Gorman and Dr. Elizabeth Nielson, Fluence is an expertise-driven educational platform that provides professional certification and training in psychedelic therapy and psychedelic integration. The company, which has trained nearly 1,000 practitioners over the past two years, works directly with licensed healthcare professionals and graduate students to advance clinical skills and knowledge, giving clinicians the tools to provide their patients with effective, compassionate, evidence-based psychedelic therapy and integration services

EEG-Powered Meditation & Sleep

Muse is a brain-sensing headband that uses real-time biofeedback to help you refocus during the day and recover overnight.

Sensorium Therapeutics is a drug discovery company developing novel FDA-approved medicines from ethnobotanically sources compounds to address a broad set of mental illnesses.

Beckley Retreats provides science-backed psilocybin retreat experiences in Jamaica and Netherlands.